title: Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.
authors.affiliation: Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Salles
authors.affiliation: Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Schuster
authors.affiliation: Department of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
authors.forename: Sven
authors.initials: S
authors.lastname: de Vos
authors.affiliation: Departments of Oncology and Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Nina D
authors.initials: ND
authors.lastname: Wagner-Johnston
authors.affiliation: Department of Internal Medicine III, University Hospital of Ulm, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Viardot
authors.affiliation: Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA.
authors.forename: Kristie A
authors.initials: KA
authors.lastname: Blum
authors.affiliation: Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Flowers
authors.affiliation: Department of Hematology, Jagiellonian University, Krakow, Poland.
authors.forename: Wojciech J
authors.initials: WJ
authors.lastname: Jurczak
authors.affiliation: Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN, USA.
authors.forename: Ian W
authors.initials: IW
authors.lastname: Flinn
authors.affiliation: Department of Medicine, Oncology Division, Washington University School of Medicine, St Louis, MO, USA.
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
authors.affiliation: Division of Hematology/Oncology, Weill Cornell Medical College, NY, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Martin
authors.affiliation: Gilead Sciences Inc., Foster City, CA, USA.
authors.forename: Yeonhee
authors.initials: Y
authors.lastname: Kim
authors.affiliation: Gilead Sciences Inc., Foster City, CA, USA.
authors.forename: Sanatan
authors.initials: S
authors.lastname: Shreay
authors.affiliation: At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA.
authors.forename: Matthias
authors.initials: M
authors.lastname: Will
authors.affiliation: At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA.
authors.forename: Bess
authors.initials: B
authors.lastname: Sorensen
authors.affiliation: At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA.
authors.forename: Madlaina
authors.initials: M
authors.lastname: Breuleux
authors.affiliation: Institute of Hematology and Oncology, University of Bologna, Italy.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.affiliation: Medical Oncology Division, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA agopal@u.washington.edu.
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Gopal
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000477:Alkylating Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D061214:Patient Safety; D011687:Purines / Q000627:therapeutic use*; D052999:Quinazolinones / Q000627:therapeutic use*; D012008:Recurrence; D012307:Risk Factors; D000069283:Rituximab / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000477:Alkylating Agents; D011687:Purines; D052999:Quinazolinones; D000069283:Rituximab; C552946:idelalisib